BridgeBio Pharma Inc
XBER:2CL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BridgeBio Pharma Inc
XBER:2CL
|
US |
|
I
|
ITM Power PLC
OTC:ITMPF
|
UK |
|
ESR-Logos REIT
F:UZ0
|
SG |
|
R
|
Renault SA
OTC:RNSDF
|
FR |
|
S
|
Suzano SA
SWB:SPXB
|
BR |
|
TotalEnergies EP Gabon
PAR:EC
|
GA |
|
A
|
Abacus Mining and Exploration Corp
OTC:ABCFF
|
CA |
|
Haitong Securities Co Ltd
F:6HT
|
CN |
|
Ziff Davis Inc
F:JXC1
|
US |
|
Centamin PLC
F:7CT
|
JE |
|
Y
|
Ynvisible Interactive Inc
OTC:YNVYF
|
CA |
|
M
|
Mosaic Co
F:02M
|
US |
|
C
|
Canada Goose Holdings Inc
NYSE:GOOS
|
CA |
|
J
|
J Sainsbury PLC
F:SUY1
|
UK |
|
Mitrabara Adiperdana Tbk PT
IDX:MBAP
|
ID |
Wall St Price Targets
2CL Price Targets Summary
BridgeBio Pharma Inc
According to Wall Street analysts, the average 1-year price target for 2CL is 0.072 EUR with a low forecast of 0.055 EUR and a high forecast of 0.112 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 2CL's stock price target?
Price Target
0.072
EUR
According to Wall Street analysts, the average 1-year price target for 2CL is 0.072 EUR with a low forecast of 0.055 EUR and a high forecast of 0.112 EUR.
What is the Revenue forecast for BridgeBio Pharma Inc?
Projected CAGR
37%
The compound annual growth rate for Revenue over the next 8 years is 37%.
What is the Gross Profit forecast for BridgeBio Pharma Inc?
Projected CAGR
36%
The compound annual growth rate for Gross Profit over the next 8 years is 36%.
